A phase II study to confirm the efficacy and safety of trametinib as single agent in NF1-associated LGG and non-NF1 gliomas with either KIAA1549-BRAF fusion or activation of the MAPK/ERK pathway, is ongoing (NCT03363217). This evidence concerns the gene KIAA1549 and central nervous system cancer.